A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34021
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and debilitating disease with limited therapeutic options. The aim of this clinical study was to evaluate the safety, efficacy and pharmacokinetics of a novel regimen comprised of… read more here.
Keywords: immunomodulatory effects; study oxiri; phase study; adenocarcinoma ... See more keywords